N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Sponsor: Mirati Therapeutics Inc. • ClinicalTrials.gov ID: NCT07415031

Registry updated: 2026-10-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Interventions

  • Adagrasib (Drug)
    Specified dose on specified days
  • Pembrolizumab (Drug)
    Specified dose on specified days
  • Cetuximab (Drug)
    Specified dose on specified days
  • Pemetrexed (Drug)
    Specified dose on specified days
  • Docetaxel (Drug)
    Specified dose on specified days
  • Irinotecan (Drug)
    Specified dose on specified days
  • Leucovorin (Drug)
    Specified dose on specified days
  • Oxaliplatin (Drug)
    Specified dose on specified days
  • Fluorouracil (Drug)
    Specified dose on specified days

Eligibility criteria

Inclusion Criteria: * Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. * Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: * Participant is not eligible for study treatment per the parent study eligibility criteria. * Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study. * Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.

Conditions

Solid Tumors

Locations

  • Local Institution - 0005 — Phoenix, Arizona, United States
  • Southern California Permanente Medical Group — Bellflower, California, United States
  • MemorialCare - Long Beach Medical Center — Long Beach, California, United States
  • Local Institution - 0003 — Newark, Delaware, United States
  • Florida Cancer Specialists - North — St. Petersburg, Florida, United States
  • Cancer Center of Kansas — Wichita, Kansas, United States
  • Local Institution - 0092 — Boston, Massachusetts, United States
  • Dana Farber Cancer Center — Boston, Massachusetts, United States
  • Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota, United States
  • Metro-Minnesota Community Oncology Research Consortium (MMCORC) — Saint Paul, Minnesota, United States
  • Nebraska Cancer Specialists — Omaha, Nebraska, United States
  • Oncology Associates Of Oregon, Pc — Eugene, Oregon, United States
  • The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee, United States
  • Texas Oncology-Bedford — Bedford, Texas, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
  • Texas Oncology - DFW — Grapevine, Texas, United States
  • PeaceHealth St. Joseph Medical Center — Bellingham, Washington, United States
  • Local Institution - 0093 — St Leonards, New South Wales, Australia
  • AZ Maria Middelares — Ghent, Belgium
  • Local Institution - 0108 — São Paulo, Brazil
  • Local Institution - 0111 — São Paulo, Brazil
  • BC Cancer - Vancouver — Vancouver, British Columbia, Canada
  • Local Institution - 0037 — Beijing, Beijing Municipality, China
  • Local Institution - 0045 — Xiamen, Fujian, China
  • Local Institution - 0042 — Zhengzhou, Henan, China
  • Local Institution - 0038 — Changsha, Hunan, China
  • Local Institution - 0046 — Nanjing, Jiangsu, China
  • Local Institution - 0048 — Nanchang, Jiangxi, China
  • Local Institution - 0049 — Shenyang, Liaoning, China
  • Local Institution - 0039 — Jinan, Shandong, China
  • Local Institution - 0047 — Linyi, Shandong, China
  • Local Institution - 0043 — Shanghai, Shanghai Municipality, China
  • Local Institution - 0040 — Chengdu, Sichuan, China
  • Local Institution - 0044 — Hangzhou, Zhejiang, China
  • Local Institution - 0041 — Xi'an, China
  • Local Institution - 0076 — Nice, Alpes-Maritimes, France
  • Centre Antoine-Lacassagne — Nice, Alpes-Maritimes, France
  • Nouvel Hôpital Civil (NHC) — Strasbourg, Alsace, France
  • Local Institution - 0103 — Pessac, Aquitaine, France
  • Chu Jean Minjoz — Besançon, Doubs, France
  • Local Institution - 0065 — La Tronche, Isère, France
  • Local Institution - 0063 — Saint-Herblain, Loire-Atlantique, France
  • Local Institution - 0050 — Saint-Herblain, Loire-Atlantique, France
  • ICO Papin — Angers, Maine-et-Loire, France
  • Hospices Civils de Lyon - Hopital Louis Pradel — Bron, Rhône, France
  • Local Institution - 0075 — Gleizé, Rhône, France
  • Local Institution - 0051 — Poitiers, Vienne, France
  • Centre Hospitalier Intercommunal de Créteil — Créteil, France
  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord — Marseille, France
  • Centre Hospitalier de Cornouaille Quimper - Concarneau — Quimper, France
  • Hôpital d'Instruction des Armées Bégin — Saint-Mandé, France
  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau — Tours, France
  • Local Institution - 0061 — Paris, Île-de-France Region, France
  • Klinikum Neuperlach — München, Germany
  • Local Institution - 0081 — Athens, Attikí, Greece
  • Local Institution - 0022 — Attiki, Greece
  • Local Institution - 0087 — Thessaloniki, Greece
  • Orszagos Koranyi Pulmonologiai Intezet — Budapest, Hungary
  • Orszagos Onkologiai Intezet — Budapest, Hungary
  • Local Institution - 0055 — Jerusalem, Jerusalem, Israel
  • Local Institution - 0119 — Haifa, Israel
  • Local Institution - 0106 — Tel Aviv, Israel
  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga — Orbassano, Piedmont, Italy
  • Istituto Nazionale Tumori Regina Elena — Rome, Roma, Italy
  • Azienda Ospedaliera Universitaria Careggi — Florence, Tuscany, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola — Bologna, Italy
  • Local Institution - 0052 — Meldola, Italy
  • Istituto Europeo di Oncologia IRCCS — Milan, Italy
  • Istituto Europeo di Oncologia IRCCS — Milan, Italy
  • Local Institution - 0079 — Pesaro, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore — Roma, Italy
  • Local Institution - 0026 — Terni (Perugia), Italy
  • Local Institution - 0110 — Tōon, Ehime, Japan
  • Local Institution - 0056 — Breda, North Brabant, Netherlands
  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) — Amsterdam, North Holland, Netherlands
  • Ziekenhuis St. Jansdal — Harderwijk, Netherlands
  • Local Institution - 0071 — Utrecht, Netherlands
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit — Gdansk, Poland
  • Local Institution - 0014 — Lisbon, Lisbon District, Portugal
  • Local Institution - 0060 — Craiova, Dolj, Romania
  • National Cancer Centre Singapore — Singapore, Singapore
  • Local Institution - 0069 — Goyang-si, Kyǒnggi-do, South Korea
  • Local Institution - 0070 — Seoul, South Korea
  • Local Institution - 0068 — Seoul, South Korea
  • CHUAC-Complejo Hospitalario Universitario A Coruña — A Coruña, A Coruña [La Coruña], Spain
  • Local Institution - 0011 — Palma, Balears [Baleares], Spain
  • Local Institution - 0010 — Barcelona, Barcelona [Barcelona], Spain
  • Institut Catala d'Oncologia-Hospital Germans Trias i Pujol — Badalona, Barcelona, Spain
  • Local Institution - 0030 — Santander, Cantabria, Spain
  • Hospital Universitario Ramón y Cajal — Madrid, Madrid, Comunidad de, Spain
  • Clinica Universidad de Navarra — Pamplona, Navarre, Spain
  • Hospital Clinico de Valencia — Valencia, Valenciana, Comunitat, Spain
  • Local Institution - 0029 — Barcelona, Spain
  • Hospital Universitario Reina Sofia — Córdoba, Spain
  • Hospital General Universitario Gregorio Marañon — Madrid, Spain
  • Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain
  • Local Institution - 0062 — Madrid, Spain
  • H.R.U Málaga - Hospital General — Málaga, Spain
  • Local Institution - 0008 — Seville, Spain
  • Local Institution - 0115 — London, London, City of, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital — Birmingham, United Kingdom
  • Leicester Royal Infirmary-HOPE Clinical Trials Unit — Leicester, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record